Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02377648
Other study ID # CART
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2015
Est. completion date December 2020

Study information

Verified date September 2021
Source Universita di Verona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CART Pilot study was designed to provide preliminary observations (about performance and safety) and generate hypotheses for future studies . The primary goal of the study is to evaluate the performance at one year of second-generation ABSORB Bioresorbable Vascular Scaffold (BVS)(Abbott Vascular, Santa Clara, CA , USA), the Everolimus Eluting Bioresorbable Vascular Scaffold, in heart transplant recipients affected by cardiac allograft vasculopathy (CAV) and significative coronary stenosis. The secondary objectives are: - to collect data about the procedural and clinical outcomes post-procedure , 30 days, 180 days and at 1,2 and 3-year follow-up, of patients who underwent ABSORB BVS implantation in order to investigate the safety of the device in CAV population; - to evaluate the progression of the disease and the its interactions with the study device by using data derived from multi-imaging invasive techniques. The vascular reparative therapy and in particular the BVS technology showing important advantages in terms of endothelial preservation, adequate vasomotion, and restoration of the media and adventitia of the vessel wall, could represent a new and more effective therapeutic option, compared to bare-metal and drug-eluting stent technologies, for transplanted patients, since all these mechanisms may, at least in part, counteract the detrimental changes leading to CAV, namely constrictive remodeling and rapid atherosclerosis progression. Subjects enrolled into the clinical study will be male or female derived from the heart transplant recipients population of every participating center. The clinical study will enroll 30 subjects. Subjects, who underwent the yearly expected coronary angiography follow-up after heart transplant surgery, meeting the general and angiographic inclusion and exclusion criteria (eligibility will be assessed by Heart Team consensus) will be asked to sign an informed consent form. Subjects who do not meet inclusion and exclusion criteria are subject to the standard follow-up of heart transplant (HTx) recipients and will undergo to an invasive evaluation after 365 ± 28 days. The study comprises two distinct phases: - the enrollment phase which starts with the recruitment of the first subject and it is planned to last one year; - the follow-up phase which is planned to last three years from the enrollment of the last patient. The total duration of the study will be of four years, including both the enrollment and the follow-up phases


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date December 2020
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - General Inclusion criteria: All the enrolled patients must be heart transplanted recipients. The inclusion criteria must follow the most recent instructions for use (IFU) for BVS which may include but are not Limited to the following: - Patient must be at least 18 years of age at the time of signing the Informed Consent Form - Patient must be eligible for percutaneous coronary intervention (PCI) - Patient is to be treated for de novo lesions located in previously untreated vessels. - Patient must agree to undergo all required follow-up visits and data collection. Angiographic inclusion criteria: • Presence of at least one critical angiographic de novo lesion (DS =70%) or a non-critical angiographic de novo lesion (50% = DS <70%) associated with concomitant signs or symptoms of myocardial ischemia. Any intermediate lesion without a clear evidence of ischemia will be interrogated by means of fractional flow reserve assessment with a pressure wire, as recommended by current international guidelines Exclusion Criteria: - General Exclusion criteria: - Inability to obtain a signed informed consent from potential patient. - Contraindications for drug eluting scaffold implantation (known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, ticlopidine, prasugrel, and ticagrelor, everolimus, poly (L-lactide), poly (D,L-lactide), or platinum, or with contrast sensitivity, who cannot be adequately premedicated). - Female patients with childbearing potential with a positive pregnancy test within 7 days prior to the index procedure. - Prior Coronary Artery Bypass Graft (CABG) at any time or planned CABG.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS =70%) or a non-critical angiographic de novo lesion (50% = DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.

Locations

Country Name City State
Italy Azienda Ospedaliera Brotzu Cagliari
Italy Azienda Ospedaliera Specialistica Dei Colli Naples
Italy Azienda Ospedaliera Di Padova Padua
Italy Fondazione Irccs Policlinico San Matteo Pavia
Italy Azienda Ospedaliera San Camillo Forlanini Rome
Italy European Hospital Rome
Italy Azienda Sanitaria Universitaria Integrata Di Udine (Asuiud) Udine
Italy Azienda Ospedaliera Universitaria Integrata Verona Verona
Netherlands Cardialysis Core Laboratory For Imaging Rotterdam
Netherlands Thoraxcenter, Universtity of Rotterdam Rotterdam

Sponsors (1)

Lead Sponsor Collaborator
Universita di Verona

Countries where clinical trial is conducted

Italy,  Netherlands, 

References & Publications (5)

Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. — View Citation

Ribichini F, Pighi M, Faggian G, Vassanelli C. Bioresorbable vascular scaffolds in cardiac allograft vasculopathy: a new therapeutic option. Am J Med. 2013 Nov;126(11):e11-4. doi: 10.1016/j.amjmed.2013.05.025. — View Citation

Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009 Mar 14;373(9667):897-910. doi: 10.1016/S0140-6736(09)60325-1. — View Citation

Taylor DO, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Rahmel AO, Kucheryavaya AY, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report--2008. J Heart Lung Transplant. 2008 Sep;27(9):943-56. doi: 10.1016/j.healun.2008.06.017. — View Citation

Tomai F, Adorisio R, De Luca L, Pilati M, Petrolini A, Ghini AS, Parisi F, Pongiglione G, Gagliardi MG. Coronary plaque composition assessed by intravascular ultrasound virtual histology: association with long-term clinical outcomes after heart transplantation in young adult recipients. Catheter Cardiovasc Interv. 2014 Jan 1;83(1):70-7. doi: 10.1002/ccd.25054. Epub 2013 Jul 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Restenosis rate (bioresorbable vascular scaffold), defined as >50% narrowing at the stent site or 5 mm proximal or distal to the stent, as assessed by Quantitative Coronary Analysis. One Year
Secondary Device success (lesion based analysis) Basal procedure
Secondary Procedural success (subject based analysis) Basal procedure
Secondary Death (cardiac, vascular, non-cardiovascular) 30 days, 180 days, 2 years and 3 years
Secondary Myocardial infarction (MI: Q wave Myocardial Infarction (QMI) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Target lesion revascularization (TLR) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Target vessel revascularization (TVR) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Non-target vessel revascularization (NTVR) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Composite (Death/All MI/ Graft failure) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Composite (Cardiac death/TV-MI/TLR ) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Composite (Cardiac death/all MI/TLR ) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Composite (Cardiac death/all MI/TVR) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Composite (Death/All MI/all revascularization) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Timing (Acute) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Timing (Subacute) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Timing (Late) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Timing (Very late) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Evidence (Definite) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Evidence (Probable) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Scaffold thrombosis Evidence (Possible) 30 days, 180 days, 1 year, 2 years and 3 years
Secondary Angiographic Endpoints In-scaffold Reference Vessel Diameter (RVD) (mm) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-scaffold Minimal Lumen Diameter (MLD) (mm) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-scaffold Diameter Stenosis (DS) (%) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-scaffold late loss (mm) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints Proximal late loss (mm) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints Distal late loss (mm) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-scaffold absolute minimal luminal area (mm2) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-scaffold minimal luminal cross sectional area (mm2) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-segment late loss (mm) In-stent binary restenosis (%) Basal procedure, 1 year and 3 years
Secondary Angiographic Endpoints In-segment binary restenosis Basal procedure, 1 year and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Vessel (EEM) area (mm2) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Vessel volume (mm3) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Average lumen area (mm2) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Lumen volume (mm3) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Plaque area (mm2) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Plaque volume (mm3) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Minimal lumen area (mm2) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Lumen area stenosis (%) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Vessel volume index (mm3/mm) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Lumen volume index (mm3/mm) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Plaque volume index (mm3/mm) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Plaque burden, % Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Projected MLD (mm) Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Dense calcium volume, area, percentage Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Necrotic core volume, area, percentage Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Fibrofatty volume, area, percentage Basal procedure and 3 years
Secondary Intravascular Ultrasound/Intravascular Ultrasound-Virtual Histology Endpoints Fibrous volume, area, percentage Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Maximal intimal thickness (MIT) (mm) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Media thickness at MIT (mm) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Mean lumen area (mm2) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Intimal area (mm2) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Maximal, minimal and mean lumen diameter (mm) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Discernible struts Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Atherosclerosis assessment (Eccentric plaque) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Atherosclerosis assessment (Calcification) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Atherosclerosis assessment (Lipid) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Vulnerable plaque assessment (thin-cap fibroatheroma) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Vulnerable plaque assessment (macrophages) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Vulnerable plaque assessment (microchannels) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Vulnerable plaque assessment (calcific nod) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Lesions assessment (Intimal laceration) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Lesions assessment (plaque rupture) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Lesions assessment (intraluminal thrombus) Basal procedure and 3 years
Secondary Optical Coherence Tomography Endpoints Lesions assessment (layered complex plaque) Basal procedure and 3 years
See also
  Status Clinical Trial Phase
Completed NCT02880137 - Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy Phase 4
Terminated NCT01848301 - Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation Phase 1
Terminated NCT01278745 - Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation Phase 2
Withdrawn NCT01812434 - Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients N/A
Withdrawn NCT01305382 - Noninvasive Evaluation of Cardiac Allograft Vasculopathy N/A
Recruiting NCT05826444 - Microvascular Cardiac Allograft Vasculopathy Trial
Suspended NCT05756088 - Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Completed NCT02013037 - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Phase 3
Withdrawn NCT01157949 - A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) Phase 3
Withdrawn NCT01305395 - Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients N/A
Enrolling by invitation NCT06147271 - Impact of SGLT2 Inhibitors in Heart Transplant Recipients Phase 2
Recruiting NCT04193306 - Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients Phase 4
Recruiting NCT02798731 - Physiologic Assessment of Microvascular Function in Heart Transplant Patients
Withdrawn NCT02777255 - Severe CAV MRI in Heart Transplant Recipient N/A
Completed NCT05373108 - Endothelin-1 and Cardiac Allograft Vasculopathy (CAV) Phase 4
Withdrawn NCT01424917 - Noninvasive Predictors of Transplant Vasculopathy N/A
Recruiting NCT04770012 - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Phase 3
Active, not recruiting NCT01078363 - Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy N/A
Completed NCT03734211 - Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients Phase 3
Recruiting NCT06089486 - MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation N/A